Thomas Pritzker to Step Down as Hyatt Executive Chairman After Epstein Ties Acknowledged 
AstroTurf Expands Footprint at Colorado as Buffaloes Complete Second Installation in 12 Months 
NAB Shares Hit Record High as First-Quarter Cash Earnings Jump 16% 
Qualcomm to Invest $150 Million in India AI Startups, Strengthening Presence in Growing Market 
Mark Zuckerberg Testifies in Youth Social Media Addiction Trial Over Instagram Policies 
OpenAI Nears $100 Billion Funding Round at $850 Billion Valuation: Bloomberg Report 
Airbus Cuts Jet Production Target Amid Pratt & Whitney Engine Shortages, Q4 Profit Jumps 17% 
Bill Gates Pulls Out of India’s AI Impact Summit Amid Controversy and Event Mismanagement 
Microsoft Plans $50 Billion AI Investment to Accelerate Growth in the Global South 
Microsoft Responds to ICE Surveillance Concerns Amid Azure Cloud Expansion 
Goldman Sachs Reportedly Drops Diversity Criteria From Board Candidate Evaluations 
Santos Wins Court Case Over Net Zero and Sustainability Claims 
Stock Market Movers: NVIDIA and Meta Expand AI Partnership as Cadence Surges on Earnings 
Yotta to Build $2 Billion AI Data Centre Hub in India with Nvidia Blackwell Ultra Chips 
Starboard Value Targets Tripadvisor Board Overhaul Amid Stock Slump 
Federal Court Fines Mobil Oil Australia A$16 Million for Misleading Fuel Claims 
CANTON, Mass., May 02, 2018 -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced that management will present at the Deutsche Bank 43rd Annual Health Care Conference on Tuesday, May 8, 2018 at 12:50 p.m. ET at the Intercontinental Hotel Boston.
About Collegium Pharmaceutical, Inc.
Collegium is a specialty pharmaceutical company focused on becoming the leader in responsible pain management by developing and commercializing innovative, differentiated products for patients suffering from pain.
About Xtampza ER
Xtampza® ER is Collegium’s first product utilizing the DETERx technology platform. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone approved by the FDA for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.
Contact:
Alex Dasalla
[email protected]
